FDA Approves Iloperidone for Schizophrenia Patients
A medication for schizophrenia, iloperidone, whose use was dropped a decade ago, has now been approved by the FDA for its originally intended use. Iloperidone, a drug from the atypical antipsychotic drug class, is a mixed dopamine D2/serotonin 5-HT2A receptor antagonist. Initial trails of the drug suggested that it was less effective than other antipsychotic drugs, including risperidone (Risperdal) and haloperidol (Haldol). However, after the rights were sold to Vanda Pharmaceuticals, new trails were initiated, which found iloperidone matched ziprasidone, another antipsychotic, in improving scores on the Positive and Negative Syndrome Scale (PANSS). Both of these drugs were scored significantly higher than placebo. Click here to read an article from Medpage Today that discusses the drug’s approval more.